RE:RE:RE:RE:Scenarios and speculationThe global immune checkpoint inhibitors market is anticipated to generate $155.1 billion by 2031.
And the global market for PD-1/PD-L1 inhibitors by itself anticipated to attain $65.7 billion by 2027.
https://www.ihealthcareanalyst.com/global-pd-1-pd-l1-inhibitors-market/
Considering that ONCY's pelareorep is anticipated to potentially expand the above immune checkpoint inhibitor market by 2-3 times, due to the synergistic efficacy of pelareorep in combination with PD-(L)1 immune checkpoint inhibitors, and anticipating that ONCY's pelareorep would occupy a significant percentage of the above referenced anticipated market, a current M&A value of US$8 + Billion is on the low side of ONCY's acquisition value.
https://finance.yahoo.com/news/immune-checkpoint-inhibitors-market-predicted-090000312.html